Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease
Evelyn Berger-Sieczkowski,Verena Endmayr,Carmen Haider,Gerda Ricken,Philipp Jauk,Stefan Macher,Walter Pirker,Birgit Högl,Anna Heidbreder,Peter Schnider,Eszter Bradley-Zechmeister,Sara Mariotto,Inga Koneczny,Raphael Reinecke,Gregor Kasprian,Corinna Weber,Melanie Bergmann,Ivan Milenkovic,Thomas Berger,Carles Gaig,Lidia Sabater,Francesc Graus,Ellen Gelpi,Romana Höftberger
DOI: https://doi.org/10.1007/s00401-023-02625-6
IF: 15.887
2023-08-31
Acta Neuropathologica
Abstract:Anti-IgLON5 disease is a rare neurological, probably autoimmune, disorder associated in many cases with a specific tauopathy. Only a few post-mortem neuropathological studies have been reported so far. Little is known about the pathogenic mechanisms that result in neurodegeneration. We investigated the neuropathology of anti-IgLON5 disease and characterized cellular and humoral inflammation. We included nine cases (six of them previously published). Median age of patients was 71 years (53–82 years), the median disease duration was 6 years (0.5–13 years), and the female to male ratio was 5:4. Six cases with a median disease duration of 9 years presented a prominent tauopathy. Five of them had a classical anti-IgLON5-related brainstem tauopathy and another presented a prominent neuronal and glial 4-repeat tauopathy, consistent with progressive supranuclear palsy (PSP). Three cases with short disease duration (median 1.25 years) only showed a primary age-related neurofibrillary pathology. Inflammatory infiltrates of T and B cells were mild to moderate and did not significantly differ between anti-IgLON5 disease cases with or without tauopathy. In contrast, we found an extensive neuropil deposition of IgG4 in the tegmentum of the brainstem, olivary nucleus, and cerebellar cortex that was most prominent in two patients with short disease duration without the typical IgLON5-related tauopathy. The IgG4 deposits were particularly prominent in the cerebellar cortex and in these regions accompanied by mild IgG1 deposits. Activated complement deposition (C9neo) was absent. Our study indicates that IgLON5-related tau pathology occurs in later disease stages and may also present a PSP-phenotype with exclusively 4-repeat neuronal and glial tau pathology. The prominent deposition of anti-IgLON5 IgG4 at predilection sites for tau pathology suggests that anti-IgLON5 antibodies precede the tau pathology. Early start of immunotherapy might prevent irreversible neuronal damage and progression of the disease, at least in a subgroup of patients.
pathology,neurosciences,clinical neurology